葛兰素史克(GSK.UK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

GSK.UK 葛兰素史克

已收盘 07-23 16:30:00 BST 延时

1,509.50

-15.00

-0.98%

最高1,539.00	最低1,504.00	成交量384.65万
今开1,519.50	昨收1,524.50	日振幅2.30%
总市值6.16万亿	流通市值5.96万亿	总股本40.78亿
成交额58.14亿	换手率0.10%	流通股本39.46亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"GSK.UK","market":"UK","secType":"STK","nameCN":"葛兰素史克","latestPrice":1509.5,"timestamp":1721748600000,"preClose":1524.5,"halted":0,"volume":3846526,"delay":15,"floatShares":3945666462,"shares":4078144160,"eps":108.857796,"marketStatus":"已收盘","marketStatusCode":5,"change":-15,"latestTime":"07-23 16:30:00 BST 延时","open":1519.5,"high":1539,"low":1504,"amount":5814027466,"amplitude":0.022958,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":108.857796,"exchange":"LSE","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721804400000},"adr":0,"adjPreClose":1524.5,"adrRate":0,"openAndCloseTimeList":[[1721718000000,1721748600000]],"volumeRatio":0.938349,"nameEN":"GLAXOSMITHKLINE","tradeCurrency":"GBX","tradeService":"SETS","exchangeMarketSize":1000},"requestUrl":"/m/hq/s/GSK.UK/wiki","defaultTab":"wiki","newsList":[{"id":"2453603360","title":"万泰生物与葛兰素史克分道扬镳，钟睒睒的九价HPV疫苗生意横生变数？","url":"https://stock-news.laohu8.com/highlight/detail?id=2453603360","media":"市场资讯","labels":["Company Corporation"],"top":-1,"share":"https://www.laohu8.com/m/news/2453603360?lang=zh_cn&edition=full","pubTime":"2024-07-23 19:26","pubTimestamp":1721733960,"startTime":"0","endTime":"0","summary":"　　签约近五年，万泰生物和全球疫苗巨头葛兰素史克关于九价疫苗的合作，终以“分手”画上句号。　　作为钟睒睒的王牌之一，万泰生物的重点项目出现变数。　　7月22日，万泰生物发布公告称，全资子公司厦门万泰沧海生物技术有限公司与葛兰素史克生物有限公司决定不再继续《关于新一代宫颈癌疫苗的开发和商业化的合作协议》项下的HPV9-AS04候选疫苗的开发和商业化合作，并于2024年7月20日签订《合作协议》终止函。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/wm/2024-07-23/doc-incfcpet7744549.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2024-07-23/doc-incfcpet7744549.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","GSK","BK1200","603392","159646","GSK.UK","BK4007","LU1829250122.USD","BK1589","BK4588","LU1981816686.USD","BK0239","BK4532"],"gpt_icon":1},{"id":"2453754573","title":"万泰生物(603392.SH)：与GSK关于新一代宫颈癌疫苗的开发和商业化的合作协议终止","url":"https://stock-news.laohu8.com/highlight/detail?id=2453754573","media":"智通财经","labels":["Company Corporation"],"top":-1,"share":"https://www.laohu8.com/m/news/2453754573?lang=zh_cn&edition=full","pubTime":"2024-07-22 17:32","pubTimestamp":1721640761,"startTime":"0","endTime":"0","summary":"智通财经APP讯，万泰生物 公告，2019年9月6日，公司全资子公司厦门万泰沧海生物技术有限公司与葛兰素史克生物有限公司签署了《关于新一代宫颈癌疫苗的开发和商业化的合作协议》。《合作协议》约定双方基于万泰沧海的大肠杆菌原核表达疫苗抗原技术和GSK的佐剂技术合作开发新一代宫颈癌疫苗。经友好协商，双方决定不再继续《合作协议》项下的HPV9-AS04候选疫苗的开发和商业化合作，并于2024年7月20日签订《合作协议》终止函。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153934.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1200","LU1981816686.USD","BK4585","BK4007","GSK.UK","LU1829250122.USD","BK0239","BK1589","159646","BK4588","GSK","603392","BK4532"],"gpt_icon":1},{"id":"2450854285","title":"TIGIT靶点命途多舛！罗氏再受挫，诺华、默沙东刹车，吉利德、GSK前景几何？","url":"https://stock-news.laohu8.com/highlight/detail?id=2450854285","media":"医药经济报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450854285?lang=zh_cn&edition=full","pubTime":"2024-07-12 18:56","pubTimestamp":1720781795,"startTime":"0","endTime":"0","summary":"作为肿瘤治疗领域的潜力靶点，TIGIT靶点药物命途多舛的研发进程，产业始终给予高度关注。这是全球首个TIGIT III期临床失败案例。2021年底，TIGIT靶点迎来商业合作热潮。短短一个月内，3个重大的制药行业合作案例将TIGIT靶点推向了前所未有的热度。然而，随着临床试验的深入，TIGIT靶点药物的实际疗效和安全性受到更严格的检验。尽管如此，罗氏并未完全放弃对TIGIT靶点的探索。诺华、默沙东“撤退”吉利德、GSK前景几何？","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407121903089f3b5288&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407121903089f3b5288&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1934455863.HKD","LU0122379950.USD","MRK","LU2468319806.SGD","IE00BJT1NW94.SGD","LU1989772840.SGD","BK4516","IE00BLSP4239.USD","LU1839511570.USD","BK4007","BK4534","BK4578","LU1585245621.USD","GILD","LU0965509283.SGD","LU0265550359.USD","IE000M9KFDE8.USD","BK4550","BK4583","LU0289739699.SGD","LU1066051498.USD","IE00BJJMRZ35.SGD","IE0002141913.USD","BK4533","LU0208291251.USD","BK4559","IE00B1BXHZ80.USD","LU1057294990.SGD","LU1989771016.USD","LU1023059063.AUD","LU0211331839.USD","LU1093756168.USD","BK4588","LU1066051225.USD","BK4566","LU1061106388.HKD","GSK.UK","LU0320765992.SGD","LU1571399168.USD","LU1066053197.SGD","LU1037948541.HKD","GSK","LU1066051811.HKD","LU1093756325.SGD","LU0058720904.USD","BK4568","NVS","IE00BBT3K403.USD","BK4139","BK4585"],"gpt_icon":0},{"id":"2448120234","title":"GSK豪掷14.5亿欧元押注mRNA疗法 跨时代品类商业机遇即将爆发？","url":"https://stock-news.laohu8.com/highlight/detail?id=2448120234","media":"21世纪经济报道","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448120234?lang=zh_cn&edition=full","pubTime":"2024-07-04 16:55","pubTimestamp":1720083359,"startTime":"0","endTime":"0","summary":"7月3日，葛兰素史克公司（GSK）和CureVacN.V.公司宣布，双方已将现有合作重组为一项新的许可协议，从而使两家公司都能优先投资并专注于各自的mRNA开发活动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202407043121997515.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407043121997515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4532","GSK.UK","GSK","BK4588","BK4007","BK4585","LU1829250122.USD"],"gpt_icon":0},{"id":"2448464953","title":"GSK(GSK.US)达成近15亿欧元协议 开发潜在“best-in-class”mRNA疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2448464953","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448464953?lang=zh_cn&edition=full","pubTime":"2024-07-04 10:33","pubTimestamp":1720060382,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，GSK和CureVac宣布，他们已将现有合作重组为一项新的许可协议，使两家公司能够优先投资并专注于各自的mRNA开发活动。根据此协议，CureVac将获得近15亿欧元的款项。自2020年以来，GSK和CureVac一直合作开发用于治疗传染病的mRNA疫苗。该协议代表了GSK在疫苗平台技术持续投资的最新一步，旨在针对每种病原体开发相匹配的最佳平台，以开发潜在“best-in-class”的疫苗。根据协议，CureVac将获得4亿欧元的预付款，以及高达10.5亿欧元的开发、监管等里程碑款项。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1145430.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","LU1829250122.USD","GSK.UK","BK4532","BK4007","GSK","BK4588"],"gpt_icon":0},{"id":"2446586200","title":"又是重磅一击 葛兰素史克(GSK.US)因RSV疫苗在美国受限而大跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2446586200","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446586200?lang=zh_cn&edition=full","pubTime":"2024-06-27 17:11","pubTimestamp":1719479460,"startTime":"0","endTime":"0","summary":"葛兰素史克股价暴跌，因为美国卫生官员建议限制年龄较大、风险较高的人群接种其RSV疫苗，此举或将降低该公司畅销疫苗的市场份额。此前，葛兰素史克在向本国供应数百万剂疫苗的合同上输给了竞争对手辉瑞，该限制性指导意见标志着葛兰素史克本周遭受的第二次打击。葛兰素史克的Arexvy疫苗在美国被批准用于50至59岁的高危人群，但该小组推迟了对这一年龄段人群的推荐建议。辉瑞公司和葛兰素史克公司在RSV疫苗的接种率上展开了激烈的竞争。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-06-27/doc-incaemym6053464.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-06-27/doc-incaemym6053464.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["GSK","BK4588","BK4585","159646","GSK.UK","BK4007","BK4532","LU1829250122.USD"],"gpt_icon":0},{"id":"2446585549","title":"更新 2-美国卫生机构缩小 RSV 疫苗范围后，葛兰素史克股价下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2446585549","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446585549?lang=zh_cn&edition=full","pubTime":"2024-06-27 17:05","pubTimestamp":1719479126,"startTime":"0","endTime":"0","summary":"葛兰素史克股价周四跌至 1 月份以来的最低点。在英国富时100指数  和欧洲STOXX 600指数  中，葛兰素史克表现垫底。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","MRNA","GSK.UK","PFE","BK4551","BK4585","IE00B19Z3581.USD","IE00BLSP4239.USD","BK4007","BK4548","LU1066051498.USD","SG9999002232.USD","BK4534","BK4592","LU0289739699.SGD","SGXZ57979304.SGD","LU0058720904.USD","LU1066053197.SGD","LU0868494617.USD","BK4533","LU0122379950.USD","BK4139","SG9999002224.SGD","SG9999011175.SGD","BK4501","IE0002270589.USD","LU1023059063.AUD","LU1829250122.USD","SG9999001176.SGD","SG9999003800.SGD","LU0456855351.SGD","LU0321505439.SGD","BK4581","SG9999013999.USD","BK4550","BK4532","BK4568","IE00B19Z3B42.SGD","LU0170899867.USD","SG9999001176.USD","LU0234572021.USD","GSK","LU1057294990.SGD","IE00BBT3K403.USD","IE00BLSP4452.SGD","LU0321505868.SGD"],"gpt_icon":0},{"id":"2446304744","title":"BUZZ-葛兰素史克在美国疾病预防控制中心缩小 RSV 疫苗使用年龄建议后业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2446304744","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446304744?lang=zh_cn&edition=full","pubTime":"2024-06-27 15:40","pubTimestamp":1719474012,"startTime":"0","endTime":"0","summary":"    6月27日 - ** 葛兰素史克  股价下跌6%，报1498便士，创1月2日以来新低** 美国疾病预防控制中心周三在其网站  上缩小了今年在老年人中使用呼吸道合胞病毒疫苗的建议范围，并暂不建议在 60 岁以下的成年人中使用。** 本月早些时候，葛兰素史克获得了美国食品及药物管理局的批准，将其疫苗的使用范围扩大到50至59岁的高危成人，但该委员会推迟批准在这一年龄组使用该疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1829250122.USD","GSK","BK4532","GSK.UK","BK4007","BK4585","BUZZ","BK4588"],"gpt_icon":0},{"id":"2446394617","title":"更新版 1-制药商葛兰素史克希望保持市场领先地位，美国顾问将考虑注射 RSV 疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2446394617","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446394617?lang=zh_cn&edition=full","pubTime":"2024-06-26 22:33","pubTimestamp":1719412398,"startTime":"0","endTime":"0","summary":"辉瑞和葛兰素史克的疫苗上市第一年的总收入就超过了 24 亿美元。分析师平均预计，葛兰素史克的 RSV 疫苗今年的销售额为 15.9 亿美元，辉瑞为 14.7 亿美元，莫德纳 为 3.7 亿美元。总部设在英国的葛兰素史克公司表示，对未能入选感到失望。试验表明，辉瑞和葛兰素史克疫苗的保护作用至少可持续两个RSV季节。在它们的临床试验中，葛兰素史克的RSV疫苗Arexvy在第二年预防严重RSV的有效率为78%，辉瑞的疫苗在第二个RSV季节的有效率为78%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","LU0234572021.USD","IE00BLSP4239.USD","PFE","SG9999001176.USD","BK4007","SG9999011175.SGD","BK4534","IE00B19Z3581.USD","LU0321505439.SGD","MRNA","SG9999002224.SGD","BK4501","SGXZ57979304.SGD","BK4550","BK4551","LU0289739699.SGD","SG9999002232.USD","LU1066051498.USD","BK4532","BK4533","BK4548","LU0170899867.USD","LU1829250122.USD","LU1057294990.SGD","LU1023059063.AUD","SG9999003800.SGD","BK4588","GSK.UK","IE00BLSP4452.SGD","BK4592","LU1066053197.SGD","IE0002270589.USD","GSK","SG9999013999.USD","LU0868494617.USD","BK4581","SG9999001176.SGD","LU0058720904.USD","BK4568","LU0321505868.SGD","IE00BBT3K403.USD","LU0456855351.SGD","IE00B19Z3B42.SGD","BK4139","BK4585"],"gpt_icon":0},{"id":"2446635056","title":"葛兰素史克希望保持市场领先地位，美国顾问将考虑 RSV 疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2446635056","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446635056?lang=zh_cn&edition=full","pubTime":"2024-06-26 18:00","pubTimestamp":1719396004,"startTime":"0","endTime":"0","summary":"今年秋季，葛兰素史克公司获得了美国食品及药物管理局的批准，将其疫苗的使用范围扩大到50至59岁的成年人，成为首个获准用于该年龄组的疫苗。辉瑞和葛兰素史克的疫苗上市第一年的总收入就超过了 24 亿美元。分析师平均预计，葛兰素史克的 RSV 疫苗今年的销售额为 15.9 亿美元，辉瑞为 14.7 亿美元，莫德纳 为 3.7 亿美元。总部设在英国的葛兰素史克公司表示，对未能入选感到失望。试验表明，辉瑞和葛兰素史克疫苗的保护作用至少可持续两个RSV季节。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","MRNA","GSK.UK","PFE","BK4551","BK4585","IE00B19Z3581.USD","IE00BLSP4239.USD","BK4007","BK4548","LU1066051498.USD","SG9999002232.USD","BK4534","BK4592","LU0289739699.SGD","SGXZ57979304.SGD","LU0058720904.USD","LU1066053197.SGD","LU0868494617.USD","BK4533","LU0122379950.USD","BK4139","SG9999002224.SGD","SG9999011175.SGD","BK4501","IE0002270589.USD","LU1023059063.AUD","LU1829250122.USD","SG9999001176.SGD","SG9999003800.SGD","LU0456855351.SGD","LU0321505439.SGD","BK4581","SG9999013999.USD","BK4550","BK4532","BK4568","IE00B19Z3B42.SGD","LU0170899867.USD","SG9999001176.USD","LU0234572021.USD","GSK","LU1057294990.SGD","IE00BBT3K403.USD","IE00BLSP4452.SGD","LU0321505868.SGD"],"gpt_icon":0},{"id":"2444735243","title":"行业组织支持制药商在 \"善达 \"癌症诉讼案中提起上诉","url":"https://stock-news.laohu8.com/highlight/detail?id=2444735243","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444735243?lang=zh_cn&edition=full","pubTime":"2024-06-20 23:01","pubTimestamp":1718895718,"startTime":"0","endTime":"0","summary":"在法官拒绝后，两家公司向她申请许可 ，直接向特拉华州最高法院提出上诉。行业组织在周四提交的文件中请求法官批准这一请求。一些原告正在对这一裁决提起上诉。2020 年，美国食品和药物管理局要求生产商从市场上撤下该药，原因是担心其活性成分雷尼替丁在长期使用或受热后会降解为一种名为 NDMA 的致癌化学物质，此后诉讼开始堆积。制药商坚称，没有证据表明 Zantac 会让使用者接触到有害的 NDMA 或导致癌症。绝大多数未决案件都发生在特拉华州。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK","GSK.UK","BK4007","LU1829250122.USD","BK4532","BK4588","BK4585","PFE"],"gpt_icon":0},{"id":"2442359454","title":"不服Zantac致癌诉讼继续审理 葛兰素史克(GSK.US)提起上诉","url":"https://stock-news.laohu8.com/highlight/detail?id=2442359454","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442359454?lang=zh_cn&edition=full","pubTime":"2024-06-11 16:25","pubTimestamp":1718094353,"startTime":"0","endTime":"0","summary":"据了解，该裁决允许超过7万起声称胃灼热药物Zantac会导致癌症的诉讼继续审理。这一裁决导致葛兰素史克股价大跌。葛兰素史克表示，如果法官拒绝上诉请求，这些公司将直接要求最高法院审理此案。葛兰素史克周一还宣布，一位声称因服用Zantac而患上乳腺癌的女性在开庭前不久放弃了诉讼。Kasza案本该成为第二起进入庭审阶段的针对Zantac的案件，第一起案件上月以葛兰素史克和勃林格殷格翰胜诉告终。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1133458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GSK","BK4532","BK4007","BK4585","BK4588","LU1829250122.USD","GSK.UK"],"gpt_icon":0},{"id":"2442016801","title":"长春高新年内大跌26%后，金赛药业“掌舵人”将进入董事会，市场反应冷淡丨钛媒体焦点","url":"https://stock-news.laohu8.com/highlight/detail?id=2442016801","media":"钛媒体APP","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442016801?lang=zh_cn&edition=full","pubTime":"2024-06-11 09:07","pubTimestamp":1718068039,"startTime":"0","endTime":"0","summary":"6月6日，长春高新（000661.SZ）发布董事会换届选举公告，公司第十届董事会提名姜云涛、金磊、王志刚、李秀峰、祝先潮、张玉智为公司第十一届董事会非独立董事候选人，并提名李春好、张春颖、张伟明为公司第十一届董事会独立董事候选人。值得注意的是，金赛药业“掌门人”金磊进入排名第二位的候选董事，有投资者表示，“按...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OGf-3JdQMYASnUDy5sbpnBlxZMpw-mvJUoW-li3rJ2QFAAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OGf-3JdQMYASnUDy5sbpnBlxZMpw-mvJUoW-li3rJ2QFAAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240611A01ASF00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240611A01ASF00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["LU1829250122.USD","BK4585","BK4532","BK4007","GSK.UK","GSK","BK4588"],"gpt_icon":0},{"id":"2442087958","title":"更新版 1-葛兰素史克要求对特拉华州允许 Zantac 案件继续审理的裁决提起上诉","url":"https://stock-news.laohu8.com/highlight/detail?id=2442087958","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442087958?lang=zh_cn&edition=full","pubTime":"2024-06-11 07:32","pubTimestamp":1718062326,"startTime":"0","endTime":"0","summary":"葛兰素史克公司说，如果她驳回上诉，这些公司将直接请求最高法院审理此案。同样在周一，葛兰素史克公司宣布，一名  声称因服用Zantac而患上乳腺癌的妇女  在开庭前不久撤诉。Kasza的律师没有立即回应置评请求。Kasza的案件将是第二起开庭审理的Zantac案件，上个月第一起案件以葛兰素史克  和勃林格殷格翰公司的胜诉而告终。一些原告正在对这一判决提起上诉。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","SG9999001176.SGD","SG9999011175.SGD","PFE","SG9999002232.USD","GSK","LU0321505439.SGD","SG9999013999.USD","SG9999003800.SGD","BK4007","IE00BLSP4239.USD","LU0234572021.USD","LU0122379950.USD","IE00B19Z3B42.SGD","LU1057294990.SGD","BK4585","GSK.UK","BK4581","BK4588","IE00BLSP4452.SGD","SG9999001176.USD","BK4550","LU1066053197.SGD","BK4533","LU1023059063.AUD","IE00BBT3K403.USD","LU0170899867.USD","LU0058720904.USD","BK4534","IE00B19Z3581.USD","BK4568","LU0456855351.SGD","SG9999002224.SGD","IE0002270589.USD","LU0868494617.USD","LU0321505868.SGD","SGXZ57979304.SGD","BK4592","BK4532","LU1066051498.USD","LU1829250122.USD"],"gpt_icon":0},{"id":"2441902511","title":"葛兰素史克(GSK.US)Arexvy获批拓宽至50至59岁年龄段 抢占RSV疫苗先机","url":"https://stock-news.laohu8.com/highlight/detail?id=2441902511","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441902511?lang=zh_cn&edition=full","pubTime":"2024-06-08 14:06","pubTimestamp":1717826807,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，葛兰素史克公司在呼吸道合胞病毒疫苗领域取得重大进展，其Arexvy疫苗获得美国食品药品监督管理局批准，用于50至59岁感染风险较高的成年人群体。这一批准使葛兰素史克成为首家在较年轻人群中获得此类疫苗批准的制药商，为其在秋季RSV高发季节前赢得了市场先机。据估计，超过1300万50至59岁的美国人存在感染RSV后产生严重后果的健康风险，这为葛兰素史克提供了巨大的潜在市场。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1133112.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1829250122.USD","159646","BK4588","GSK.UK","BK4585","GSK","BK4007","BK4532"],"gpt_icon":0},{"id":"2441014991","title":"美国 FDA 将葛兰素史克 RSV 疫苗的批准范围扩大至 50 至 59 岁的成年人","url":"https://stock-news.laohu8.com/highlight/detail?id=2441014991","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441014991?lang=zh_cn&edition=full","pubTime":"2024-06-08 06:02","pubTimestamp":1717797777,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透6月7日 - 美国食品和药物管理局周五批准扩大葛兰素史克公司  呼吸道合胞病毒疫苗在50至59岁成人中的使用范围，这是该年龄组首次获准使用该疫苗。这种名为Arexvy的疫苗已被批准用于60岁及以上人群。竞争对手辉瑞公司  和莫德纳公司  的疫苗也被批准用于60岁及以上的成年人。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999003800.SGD","SG9999001176.SGD","BK4534","LU1023059063.AUD","PFE","GSK","SG9999002232.USD","IE00BBT3K403.USD","LU1066051498.USD","BK4532","GSK.UK","BK4533","LU1057294990.SGD","BK4139","LU0234572021.USD","IE0002270589.USD","IE00B19Z3B42.SGD","MRNA","BK4501","LU0058720904.USD","BK4568","LU0868494617.USD","LU1066053197.SGD","BK4581","LU0122379950.USD","LU0289739699.SGD","SG9999011175.SGD","SG9999002224.SGD","BK4548","LU0456855351.SGD","LU1829250122.USD","SG9999013999.USD","IE00B19Z3581.USD","BK4585","BK4551","BK4592","IE00BLSP4452.SGD","BK4550","BK4007","IE00BLSP4239.USD","SG9999001176.USD","LU0170899867.USD","SGXZ57979304.SGD","BK4588"],"gpt_icon":0},{"id":"2441264713","title":"隔夜美股全复盘(6.5)| 英伟达续涨逾1%，股价创历史新高，苹果接近回到“3万亿”俱乐部","url":"https://stock-news.laohu8.com/highlight/detail?id=2441264713","media":"格隆汇","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441264713?lang=zh_cn&edition=full","pubTime":"2024-06-05 07:24","pubTimestamp":1717543474,"startTime":"0","endTime":"0","summary":"英伟达续涨逾1%，股价创历史新高，苹果接近回到“3万亿”俱乐部","market":"sg","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/772629","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["LU0072462426.USD","LU0795875086.SGD","LU0359202008.SGD","LU0348825331.USD","PARA","03145","LU2491050154.USD","LU0061474705.USD","LU1712237335.SGD","LU1914381329.SGD","TSM","LU0082616367.USD","LU0327786744.USD","LU0795875169.SGD","LU2237438978.USD","LU1732800096.USD","LU2491050071.SGD","LU0308772762.SGD","LU1720051108.HKD","LU0689472784.USD","GSK","LU1814569148.SGD","NVO","IE00B1XK9C88.USD","LLY","NVDA","LU0593848301.USD","LU1623119135.USD","GSK.UK","LU2491049909.HKD","LU1057294990.SGD","LU0541502299.USD","AAPL","LU0053666078.USD","LU0882574055.USD","LU0456855351.SGD","LU0912757837.SGD","LU0719512351.SGD","LU0238689110.USD","LU0211328371.USD","LU0289960550.SGD","LU1093756168.USD","LU1548497426.USD","LU1829250122.USD","STM","LU0198837287.USD","TCOM","LU2063271972.USD","ABBV","IE00BFSS8Q28.SGD"],"gpt_icon":0},{"id":"2440211594","title":"GSK(GSK.US)单抗一线疗法2期临床试验取得100%临床完全缓解率","url":"https://stock-news.laohu8.com/highlight/detail?id=2440211594","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440211594?lang=zh_cn&edition=full","pubTime":"2024-06-04 10:27","pubTimestamp":1717468021,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，6月4日，GSK宣布其PD-1抑制剂Jemperli替代手术作为错配修复缺陷局部晚期直肠癌一线疗法2期临床试验的更新长期数据。根据新闻稿，该试验在42名完成Jemperli治疗的患者中显示出“前所未见”的100%临床完全缓解率，前24例评估患者在中位随访26.3个月期间，观察到持续的临床完全缓解。Jemperli在2021年4月获美国FDA批准，作为在先前接受过含铂疗法后的dMMR晚期或复发性子宫内膜癌的单药治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1130557.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","BK4007","GSK.UK","BK1576","LU1829250122.USD","BK4585","BK4532","BK4588","GSK","BK1583","BK1141"],"gpt_icon":0},{"id":"2440765495","title":"葛兰素史克盘中异动 股价大跌7.82%报41.27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2440765495","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440765495?lang=zh_cn&edition=full","pubTime":"2024-06-03 21:32","pubTimestamp":1717421544,"startTime":"0","endTime":"0","summary":"北京时间2024年06月03日21时32分，葛兰素史克股票出现波动，股价大幅跳水7.82%。葛兰素史克股票所在的制药行业中，整体涨幅为0.08%。消息层面，截至21时32分，《法官裁定Zantac致癌诉讼继续审理，葛兰素史克盘前跌逾9%》资讯为影响葛兰素史克的重要信息。这一发现引发了全球范围内对Zantac的召回，并导致包括葛兰素史克在内的多家制药企业的市值大幅蒸发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406032132259f156bfc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406032132259f156bfc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GSK.UK","BK4007","LU1829250122.USD","BK4588","BK4585","BK4532","GSK"],"gpt_icon":0},{"id":"2440453961","title":"更新 1-7 万件 Zantac 诉讼案获准继续审理，葛兰素史克股价暴跌 9","url":"https://stock-news.laohu8.com/highlight/detail?id=2440453961","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440453961?lang=zh_cn&edition=full","pubTime":"2024-06-03 15:40","pubTimestamp":1717400448,"startTime":"0","endTime":"0","summary":"葛兰素史克表示不同意这一判决，并将立即上诉。截至格林尼治标准时间7:27，葛兰素史克股价下跌9.8%，报1596便士。判决作出后，摩根大通的分析师表示，葛兰素史克在诉讼中可能面临的潜在责任可能高于市场假设的 20 亿至 30 亿美元的潜在责任。然而，Zantac的前制造商葛兰素史克、辉瑞  、赛诺菲  和勃林格殷格翰认为，专家证人的意见缺乏科学依据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","SG9999013999.USD","SG9999001176.SGD","IE00BBT3K403.USD","SG9999003800.SGD","BK4568","GSK.UK","BK4592","IE00BLSP4452.SGD","LU0170899867.USD","LU1829250122.USD","BK4532","IE0002270589.USD","BK4534","IE00B19Z3581.USD","PFE","BK4007","BK4581","LU1066053197.SGD","LU0868494617.USD","IE00BLSP4239.USD","SG9999002232.USD","LU1066051498.USD","LU0289739699.SGD","GSK","LU1023059063.AUD","LU1057294990.SGD","LU0234572021.USD","BK4533","BK4550","BK4585","BK4588","SG9999001176.USD","SG9999011175.SGD","IE00B19Z3B42.SGD","SGXZ57979304.SGD","SG9999002224.SGD","LU0456855351.SGD","LU0122379950.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gsk.com","stockEarnings":[{"period":"1week","weight":0.0177},{"period":"1month","weight":-0.0466},{"period":"3month","weight":-0.0689},{"period":"6month","weight":-0.0017},{"period":"1year","weight":0.1411},{"period":"ytd","weight":0.0703}],"compareEarnings":[{"period":"1week","weight":0.0023},{"period":"1month","weight":-0.0042},{"period":"3month","weight":0.027},{"period":"6month","weight":0.109},{"period":"1year","weight":0.1098},{"period":"ytd","weight":0.0803}],"compareStock":{"symbol":"ISF.UK","name":"FTSE100 ETF"},"description":"GSK Plc于1999年12月6日在英国成立的公众服务有限公司，是一个世界领先的研究型制药和保健公司，由 Glaxo Wellcome plc和SmithKline Beecham plc合并而成。公司致力于开发较现有治疗方案明显改善的新产品，为病人和政府、保险公司或其他第三方提供帮助。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.013575},{"month":2,"riseRate":0.541667,"avgChangeRate":-0.00121},{"month":3,"riseRate":0.625,"avgChangeRate":0.009039},{"month":4,"riseRate":0.75,"avgChangeRate":0.03211},{"month":5,"riseRate":0.416667,"avgChangeRate":-0.009346},{"month":6,"riseRate":0.541667,"avgChangeRate":-0.000138},{"month":7,"riseRate":0.458333,"avgChangeRate":-0.002713},{"month":8,"riseRate":0.521739,"avgChangeRate":-0.003921},{"month":9,"riseRate":0.565217,"avgChangeRate":-0.000863},{"month":10,"riseRate":0.434783,"avgChangeRate":-0.000676},{"month":11,"riseRate":0.391304,"avgChangeRate":-0.007441},{"month":12,"riseRate":0.608696,"avgChangeRate":0.015835}],"exchange":"LSE","name":"葛兰素史克","nameEN":"GLAXOSMITHKLINE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"葛兰素史克(GSK.UK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供葛兰素史克(GSK.UK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"葛兰素史克,GSK.UK,葛兰素史克股票,葛兰素史克股票老虎,葛兰素史克股票老虎国际,葛兰素史克行情,葛兰素史克股票行情,葛兰素史克股价,葛兰素史克股市,葛兰素史克股票价格,葛兰素史克股票交易,葛兰素史克股票购买,葛兰素史克股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"葛兰素史克(GSK.UK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供葛兰素史克(GSK.UK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}